Addus HomeCare (NASDAQ:ADUS) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Addus HomeCare (NASDAQ:ADUS) posted its earnings results on Monday. The company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.02, Briefing.com reports. Addus HomeCare had a net margin of 6.18% and a return on equity of 9.81%. The company had revenue of $289.80 million for the quarter, compared to analyst estimates of $289.42 million. During the same period last year, the business posted $1.03 earnings per share. The business’s revenue for the quarter was up 7.1% compared to the same quarter last year.

Addus HomeCare Trading Down 0.6 %

Shares of NASDAQ:ADUS traded down $0.74 on Thursday, reaching $130.22. 27,067 shares of the company’s stock were exchanged, compared to its average volume of 131,518. The company has a fifty day moving average of $129.75 and a 200-day moving average of $120.92. Addus HomeCare has a twelve month low of $81.51 and a twelve month high of $136.12. The company has a market capitalization of $2.36 billion, a price-to-earnings ratio of 29.97, a PEG ratio of 2.29 and a beta of 1.04.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ADUS shares. Oppenheimer increased their price objective on shares of Addus HomeCare from $140.00 to $145.00 and gave the stock an “outperform” rating in a research report on Monday, September 23rd. Macquarie reaffirmed an “outperform” rating and issued a $139.00 target price on shares of Addus HomeCare in a research report on Monday. KeyCorp assumed coverage on shares of Addus HomeCare in a research report on Friday, October 11th. They issued an “overweight” rating and a $150.00 target price for the company. Stephens raised their target price on shares of Addus HomeCare from $143.00 to $145.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Royal Bank of Canada decreased their price objective on shares of Addus HomeCare from $141.00 to $136.00 and set an “outperform” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.63.

Insiders Place Their Bets

In other Addus HomeCare news, Director Esteban Lopez sold 500 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $127.50, for a total transaction of $63,750.00. Following the transaction, the director now owns 3,366 shares in the company, valued at $429,165. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Addus HomeCare news, Director Esteban Lopez sold 500 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $127.50, for a total transaction of $63,750.00. Following the transaction, the director now owns 3,366 shares in the company, valued at $429,165. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael D. Wattenbarger sold 21,917 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $133.29, for a total transaction of $2,921,316.93. Following the sale, the executive vice president now owns 7,215 shares in the company, valued at $961,687.35. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,917 shares of company stock worth $3,050,082 in the last quarter. Corporate insiders own 4.60% of the company’s stock.

About Addus HomeCare

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.